RESEARCH - Favorable Phase I results for CCX168

[Guest guest]

ChemoCentryx Reports Positive Phase I Results For CCX168, A Novel C5aR

Antagonist, At The Annual American College Of Rheumatology Meeting

(ACR)

MedicalNewsToday.com

Article Date: 11 Nov 2010 - 4:00 PST

ChemoCentryx, Inc., announced favorable Phase I results for CCX168 at

the Annual American College of Rheumatology Meeting (ACR). CCX168, the

Company's orally-active small molecule antagonist, is designed to

target the receptor for the pro-inflammatory protein known as

'complement 5a' (C5a), a so-called anaphylatoxin that drives

inflammatory responses associated with autoimmune diseases such as

vasculitis, aged-related macular degeneration, rheumatoid arthritis

and related pathologies. Data from Phase I clinical trials showed that

CCX168 exhibited an excellent safety profile, while producing greater

than 90% receptor blockade of inflammatory cells in the blood

throughout the day. Additionally, data from preclinical studies using

transgenic mice (which express human C5aR) demonstrated robust

efficacy of CCX168 in a vasculitis model. CCX168 is poised to enter

Phase II clinical development for the treatment of patients with renal

vasculitis.

**************************************

Read the rest of the article here:

http://www.medicalnewstoday.com/articles/207447.php

Not an MD